Lambert–Eaton myasthenic syndrome – Diagnosis, pathogenesis and therapy

Lambert–Eaton myasthenic syndrome – Diagnosis, pathogenesis and therapy
复制标题

兰伯特·伊顿肌无力综合征 â 诊断、发病机制和治疗

DOI:
10.1016/j.clinph.2014.06.031
复制
发表时间:
2014
影响因子:
4.7
通讯作者:
Hashemolhosseini
Hashemolhosseini
中科院分区:
医学3区
文献类型:
--
作者:
Hülsbrink;Hashemolhosseini

文献摘要

参考文献

被引文献

相似文献

Lambert-Eaton肌无力综合征(LEMS)描述了一种罕见的神经肌肉接头(NMJ)人类自身免疫性疾病。临床上,LEMS患者患有特征性的肌肉无力,这是由针对他们的电压门控钙通道(VGCC)的抗体的存在引起的。这些通道定位于其运动神经末梢的突触前膜中。自身免疫抗体与VGCC结合导致神经肌肉传递减少。在大约50%的患者中,LEMS表现为副肿瘤性表现,最常见的是与小细胞肺癌(SCLC)有关,小细胞肺癌的细胞在质膜上也表达VGCC。更好地了解LEMS的病理生理机制有助于开发新的诊断方法,并导致有针对性的对症和免疫抑制治疗。对于有潜在恶性肿瘤的LEMS患者,肿瘤治疗是迄今为止的首选。
Lambert–Eaton myasthenic syndrome (LEMS) describes a rare human autoimmune disorder of the neuromuscular junction (NMJ). Clinically, LEMS patients suffer from characteristic muscle weakness that is caused by the presence of antibodies directed against their voltage-gated calcium channels (VGCC). These channels are localized in the presynaptic membrane of their motor nerve terminals. Binding of autoimmune antibodies to the VGCCs leads to reduced neuromuscular transmission. In approximately 50% of the patients, LEMS is reflected by a paraneoplastic manifestation and most commonly associated with a small cell lung carcinoma (SCLC) whose cells also express VGCCs in their plasma membrane. Better understanding of the pathophysiological mechanisms of LEMS has helped with the development of new diagnostic approaches and has led to targeted symptomatic and immunosuppressive therapy. For LEMS patients with an underlying malignancy, tumor therapy is the first choice to date.
钙通道肽可在大鼠中引起自身免疫介导的兰伯特-伊顿肌无力综合征模型
DOI: --
发表时间: 1999
期刊: Journal of Neurological Sciences
影响因子: --
作者:
K. Komai;K. Iwasa;M. Takamori
通讯作者: M. Takamori
兰伯特-伊顿肌无力综合征中重组突触结合蛋白和钙通道亚型的抗体
DOI: --
发表时间: 1995
期刊: Journal of Neurological Sciences
影响因子: --
作者:
M. Takamori;Masami Takahashi;Y. Yasukawa;K. Iwasa;Y. Nemoto;A. Suenaga;S. Nagataki;Tatsufumi Nakamura
通讯作者: Tatsufumi Nakamura
兰伯特-伊顿肌无力综合征 IgG 对小鼠运动神经末梢的作用
DOI: --
发表时间: 1985
影响因子: 11.2
作者:
C. Prior;B. Lang;D. Wray;J. Newsom
通讯作者: J. Newsom
DOI: --
发表时间: 1995
影响因子: --
作者:
S. K. Agarawal;B. R. P. Birch;G. F. Abercrombie
通讯作者: G. F. Abercrombie
DOI: 10.1196/annals.1405.030
发表时间: 2008-01-01
期刊: MYASTHENIA GRAVIS AND RELATED DISORDERS: 11TH INTERNATIONAL CONFERENCE
影响因子: --
作者:
Titulaer, Maarten J.;Verschuuren, Jan J. G. M.
通讯作者: Verschuuren, Jan J. G. M.